PE20020744A1 - Proteccion y mejoramiento de celulas, tejidos y organos que responden a la eritropoyetina - Google Patents
Proteccion y mejoramiento de celulas, tejidos y organos que responden a la eritropoyetinaInfo
- Publication number
- PE20020744A1 PE20020744A1 PE2001001314A PE2001001314A PE20020744A1 PE 20020744 A1 PE20020744 A1 PE 20020744A1 PE 2001001314 A PE2001001314 A PE 2001001314A PE 2001001314 A PE2001001314 A PE 2001001314A PE 20020744 A1 PE20020744 A1 PE 20020744A1
- Authority
- PE
- Peru
- Prior art keywords
- erythropoyetin
- molecule
- modified
- improvement
- protection
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Gastroenterology & Hepatology (AREA)
- Obesity (AREA)
- Zoology (AREA)
- Ophthalmology & Optometry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Rheumatology (AREA)
Abstract
SE REFIERE AL USO DE LA ERITROPOYETINA SELECCIONADA DE: a) UNA ERITROPOYETINA QUE AL MENOS NO TIENE PARTES DE ACIDO SIALICO; b) UNA ERITROPOYETINA QUE AL MENOS NO TIENE CARBOHIDRATOS DE ENLACE A N O ENLACE A OXIGENO; c) UNA ERITROPOYETINA QUE TIENE AL MENOS UN CONTENIDO REDUCIDO DE CARBOHIDRATO; d) UNA ERITROPOYETINA CON UNA PORCION DE CARBOHIDRATO DE LA MOLECULA DE ERITROPOYETINA MODIFICADA QUE TIENE AL MENOS UN PATRON DE GLUCOSILACION; e) UNA ERITROPOYETINA QUE TIENE AL MENOS UNO O MAS CARBOHIDRATOS OXIDADOS QUE PUEDEN SER REDUCIDOS QUIMICAMENTE; f) UNA ERITROPOYETINA QUE TIENE AL MENOS UNO O MAS RESIDUOS DE ARGININA MODIFICADOS, ENTRE OTROS. LA ASOCIACION ENTRE LA MOLECULA A SER TRANSPORTADA Y LA ERITROPOYETINA ES UN ENLACE COVALENTE LABIL, ESTABLE. LA MOLECULA ADECUADA PARA EL TRANSPORTE INCLUYE HORMONAS COMO LA HORMONA DE CRECIMIENTO, ANTIBIOTICOS, AGENTES ANTICANCERIGENOS. OTRO ASPECTO DE LA INVENCION CONSISTE EN PROPORCIONAR METODOS PARA FACILITAR LA TRANSCITOSIS DE UNA MOLECULA A TRAVES DE UNA BARRERA CELULAR ENDOTELIAL POR ADMINISTRACION DE UNA MOLECULA EN ASOCIACION CON UNA ERITROPOYETINA MODIFICADA. SE REFIERE TAMBIEN AL USO DE DERIVADOS DE ERITROPOYETINA PARA LA PREPARACION DE COMPOSICIONES FARMACEUTICAS PARA LA PROTECCION, MANTENIMIENTO, MEJORAMIENTO, RECUPERACION DE LA FUNCION O VIABILIDAD DE CELULAS DISTANTES A LA VASCULATURA
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25924500P | 2000-12-29 | 2000-12-29 | |
| US09/753,132 US6531121B2 (en) | 2000-12-29 | 2000-12-29 | Protection and enhancement of erythropoietin-responsive cells, tissues and organs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20020744A1 true PE20020744A1 (es) | 2002-08-21 |
Family
ID=26947185
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2011000084A PE20110236A1 (es) | 2000-12-29 | 2001-12-28 | Proteccion y mejoramiento de celulas, tejidos y organos que responden a la eritropoyetina |
| PE2001001314A PE20020744A1 (es) | 2000-12-29 | 2001-12-28 | Proteccion y mejoramiento de celulas, tejidos y organos que responden a la eritropoyetina |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2011000084A PE20110236A1 (es) | 2000-12-29 | 2001-12-28 | Proteccion y mejoramiento de celulas, tejidos y organos que responden a la eritropoyetina |
Country Status (33)
| Country | Link |
|---|---|
| EP (2) | EP2281828A3 (es) |
| JP (4) | JP2005502584A (es) |
| KR (3) | KR20080041755A (es) |
| CN (2) | CN1505638A (es) |
| AR (1) | AR035412A1 (es) |
| AU (1) | AU2002239665B2 (es) |
| BG (1) | BG108030A (es) |
| BR (1) | BR0116587A (es) |
| CA (1) | CA2432853A1 (es) |
| CL (1) | CL2010000606A1 (es) |
| CZ (1) | CZ20032059A3 (es) |
| DO (1) | DOP2001000321A (es) |
| EA (1) | EA007967B1 (es) |
| EE (1) | EE200300267A (es) |
| ES (1) | ES2564552T3 (es) |
| HR (1) | HRP20030515A2 (es) |
| HU (1) | HUP0302549A3 (es) |
| IL (2) | IL156399A0 (es) |
| IS (1) | IS6843A (es) |
| MX (1) | MXPA03005893A (es) |
| NO (1) | NO332038B1 (es) |
| NZ (2) | NZ526722A (es) |
| PA (1) | PA8536201A1 (es) |
| PE (2) | PE20110236A1 (es) |
| PH (1) | PH12016500941A1 (es) |
| PL (1) | PL365876A1 (es) |
| RS (1) | RS52276B (es) |
| SK (1) | SK9572003A3 (es) |
| SV (1) | SV2003000814A (es) |
| UA (1) | UA91321C2 (es) |
| UY (1) | UY27111A1 (es) |
| WO (1) | WO2002053580A2 (es) |
| ZA (1) | ZA200304551B (es) |
Families Citing this family (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7297680B2 (en) | 1999-04-15 | 2007-11-20 | Crucell Holland B.V. | Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content |
| US6855544B1 (en) | 1999-04-15 | 2005-02-15 | Crucell Holland B.V. | Recombinant protein production in a human cell |
| US7604960B2 (en) | 1999-04-15 | 2009-10-20 | Crucell Holland B.V. | Transient protein expression methods |
| US8236561B2 (en) | 1999-04-15 | 2012-08-07 | Crucell Holland B.V. | Efficient production of IgA in recombinant mammalian cells |
| US7527961B2 (en) | 1999-11-26 | 2009-05-05 | Crucell Holland B.V. | Production of vaccines |
| US7192759B1 (en) | 1999-11-26 | 2007-03-20 | Crucell Holland B.V. | Production of vaccines |
| US7521220B2 (en) | 1999-11-26 | 2009-04-21 | Crucell Holland B.V. | Production of vaccines |
| PA8536201A1 (es) * | 2000-12-29 | 2002-08-29 | Kenneth S Warren Inst Inc | Protección y mejoramiento de células, tejidos y órganos que responden a la eritropoyetina |
| US20030072737A1 (en) * | 2000-12-29 | 2003-04-17 | Michael Brines | Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs |
| EP1930023A3 (en) * | 2001-04-09 | 2008-08-06 | East Carolina University | Erythropoietin ameliorates chemotherapy-induced toxicity in vivo |
| US7696163B2 (en) | 2001-10-10 | 2010-04-13 | Novo Nordisk A/S | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
| US7173003B2 (en) | 2001-10-10 | 2007-02-06 | Neose Technologies, Inc. | Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF |
| US7795210B2 (en) | 2001-10-10 | 2010-09-14 | Novo Nordisk A/S | Protein remodeling methods and proteins/peptides produced by the methods |
| US7157277B2 (en) | 2001-11-28 | 2007-01-02 | Neose Technologies, Inc. | Factor VIII remodeling and glycoconjugation of Factor VIII |
| US7214660B2 (en) | 2001-10-10 | 2007-05-08 | Neose Technologies, Inc. | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
| EP1465987B1 (en) | 2001-12-07 | 2008-01-23 | Crucell Holland B.V. | Production of viruses, viral isolates and vaccines |
| DE10219545A1 (de) * | 2002-04-26 | 2003-11-06 | Lang Florian | Regulation der Apoptose |
| DE10234192B4 (de) | 2002-07-26 | 2009-11-26 | Epoplus Gmbh Co.Kg | Verwendung von Erythropoetin |
| ES2420581T3 (es) | 2003-03-14 | 2013-08-26 | Biogenerix Gmbh | Polímeros solubles en agua ramificados y sus conjugados |
| EP1615945B1 (en) | 2003-04-09 | 2011-09-28 | BioGeneriX AG | Glycopegylation methods and proteins/peptides produced by the methods |
| US8791070B2 (en) | 2003-04-09 | 2014-07-29 | Novo Nordisk A/S | Glycopegylated factor IX |
| US7718363B2 (en) | 2003-04-25 | 2010-05-18 | The Kenneth S. Warren Institute, Inc. | Tissue protective cytokine receptor complex and assays for identifying tissue protective compounds |
| WO2004103275A2 (en) | 2003-05-09 | 2004-12-02 | Neose Technologies, Inc. | Compositions and methods for the preparation of human growth hormone glycosylation mutants |
| CA2520891C (en) | 2003-05-09 | 2014-07-08 | Crucell Holland B.V. | Cultures of e1-immortalized cells and processes for culturing the same to increase product yields therefrom |
| US9005625B2 (en) | 2003-07-25 | 2015-04-14 | Novo Nordisk A/S | Antibody toxin conjugates |
| US7645733B2 (en) * | 2003-09-29 | 2010-01-12 | The Kenneth S. Warren Institute, Inc. | Tissue protective cytokines for the treatment and prevention of sepsis and the formation of adhesions |
| US8633157B2 (en) | 2003-11-24 | 2014-01-21 | Novo Nordisk A/S | Glycopegylated erythropoietin |
| US20080305992A1 (en) | 2003-11-24 | 2008-12-11 | Neose Technologies, Inc. | Glycopegylated erythropoietin |
| US20060040856A1 (en) | 2003-12-03 | 2006-02-23 | Neose Technologies, Inc. | Glycopegylated factor IX |
| US7956032B2 (en) | 2003-12-03 | 2011-06-07 | Novo Nordisk A/S | Glycopegylated granulocyte colony stimulating factor |
| JP5743368B2 (ja) | 2004-01-08 | 2015-07-01 | ラショファーム ゲーエムベーハー | ペプチドのｏ結合型グリコシル化 |
| JP2008505184A (ja) * | 2004-07-02 | 2008-02-21 | ザ ケネス エス．ウォーレン インスティテュート，インコーポレーテッド | 完全にカルバミル化されたエリトロポイエチンを生成する方法 |
| PL1781697T3 (pl) * | 2004-07-07 | 2009-10-30 | H Lundbeck As | Nowa karbamylowana EPO i sposób jej wytwarzania |
| US20080300173A1 (en) | 2004-07-13 | 2008-12-04 | Defrees Shawn | Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1] |
| EP1799249A2 (en) | 2004-09-10 | 2007-06-27 | Neose Technologies, Inc. | Glycopegylated interferon alpha |
| US20080176790A1 (en) | 2004-10-29 | 2008-07-24 | Defrees Shawn | Remodeling and Glycopegylation of Fibroblast Growth Factor (Fgf) |
| AT500929B1 (de) | 2004-11-09 | 2007-03-15 | Medizinische Uni Wien Muw | Pharmazeutische zubereitung die erythropoietin enthält |
| CN101090973B (zh) * | 2004-12-30 | 2012-03-28 | 克鲁塞尔荷兰公司 | 从表达腺病毒e1a蛋白的细胞中获得唾液酸化增加的重组蛋白质的方法及由此获得的蛋白质 |
| US9029331B2 (en) | 2005-01-10 | 2015-05-12 | Novo Nordisk A/S | Glycopegylated granulocyte colony stimulating factor |
| WO2006079155A1 (en) * | 2005-01-25 | 2006-08-03 | Apollo Life Sciences Limited | Molecules and chimeric molecules thereof |
| US20070154992A1 (en) | 2005-04-08 | 2007-07-05 | Neose Technologies, Inc. | Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants |
| JP5216580B2 (ja) | 2005-05-25 | 2013-06-19 | ノヴォ ノルディスク アー／エス | グリコペグ化第ｉｘ因子 |
| WO2006127910A2 (en) | 2005-05-25 | 2006-11-30 | Neose Technologies, Inc. | Glycopegylated erythropoietin formulations |
| UA100222C2 (uk) | 2005-08-05 | 2012-12-10 | Араім Фармасьютікалз, Інк. | Тканинозахисні пептиди і їх застосування |
| JPWO2007020922A1 (ja) * | 2005-08-17 | 2009-02-26 | 創 戸苅 | 脳疾患の治療剤および予防剤 |
| US20070105755A1 (en) | 2005-10-26 | 2007-05-10 | Neose Technologies, Inc. | One pot desialylation and glycopegylation of therapeutic peptides |
| US20090048440A1 (en) | 2005-11-03 | 2009-02-19 | Neose Technologies, Inc. | Nucleotide Sugar Purification Using Membranes |
| CN101365719A (zh) | 2006-01-18 | 2009-02-11 | 中外制药株式会社 | 唾液酸的去除方法及去唾液酸促红细胞生成素的制备方法 |
| US20080242607A1 (en) | 2006-07-21 | 2008-10-02 | Neose Technologies, Inc. | Glycosylation of peptides via o-linked glycosylation sequences |
| US20100075375A1 (en) | 2006-10-03 | 2010-03-25 | Novo Nordisk A/S | Methods for the purification of polypeptide conjugates |
| AR065613A1 (es) * | 2007-03-09 | 2009-06-17 | Chugai Pharmaceutical Co Ltd | Agentes de proteccion para organos transplantados |
| KR20100016160A (ko) | 2007-04-03 | 2010-02-12 | 바이오제너릭스 에이지 | 글리코페길화 ｇ―ｃｓｆ를 이용하는 치료 방법 |
| MX2009013259A (es) | 2007-06-12 | 2010-01-25 | Novo Nordisk As | Proceso mejorado para la produccion de azucares de nucleotidos. |
| US8207112B2 (en) | 2007-08-29 | 2012-06-26 | Biogenerix Ag | Liquid formulation of G-CSF conjugate |
| SG10201604530SA (en) | 2008-01-22 | 2016-07-28 | Araim Pharmaceuticals Inc | Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage |
| WO2009102021A1 (ja) * | 2008-02-14 | 2009-08-20 | Kyoto University | 骨髄由来幹細胞、前駆細胞機能賦活による網膜疾患治療 |
| US20130189239A1 (en) | 2008-02-27 | 2013-07-25 | Novo Nordisk A/S | Conjugated Factor VIII Molecules |
| EP2297197B1 (en) * | 2008-05-29 | 2012-03-07 | HanAll Biopharma Co., Ltd. | Modified erythropoietin (epo)polypeptides that exhibit increased protease resistance and pharmaceutical compositions thereof |
| PE20110832A1 (es) | 2008-09-26 | 2011-11-24 | Ambrx Inc | Polipeptidos de eritropoyetina felina modificados |
| DK2590666T3 (en) | 2010-07-06 | 2017-07-17 | Augustinus Bader | TOPICAL APPLICATION OF ERYTHROPOIETIN FOR USE IN THE TREATMENT OF DAMAGE OF THE CORNS |
| US20150119325A1 (en) | 2012-05-29 | 2015-04-30 | North Carolina Central University | Methods for the production of cytoprotective asialo-erythropoietin in plants and its purification from plant tissues |
| WO2017189988A1 (en) | 2016-04-29 | 2017-11-02 | Araim Pharmaceuticals, Inc. | Tissue protective peptides for preventing and treating diseases and disorders associated with tissue damage |
| WO2018011302A1 (en) * | 2016-07-12 | 2018-01-18 | Hexal Ag | Glycoprotein with reduced acetylation rate of sialic acid residues |
| RU2709833C1 (ru) * | 2019-06-13 | 2019-12-23 | Федеральное государственное автономное образовательное учреждение высшего образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") | Способ коррекции микроциркуляции в плаценте асиалированным эритропоэтином при ADMA-подобной модели преэклампсии |
| RU2707060C1 (ru) * | 2019-06-14 | 2019-11-21 | Федеральное государственное автономное образовательное учреждение высшего образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") | Способ коррекции эндотелиальной дисфункции асиалированным эритропоэтином при ADMA-подобной модели преэклампсии |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4215051A (en) | 1979-08-29 | 1980-07-29 | Standard Oil Company (Indiana) | Formation, purification and recovery of phthalic anhydride |
| KR850004274A (ko) * | 1983-12-13 | 1985-07-11 | 원본미기재 | 에리트로포이에틴의 제조방법 |
| US4703008A (en) | 1983-12-13 | 1987-10-27 | Kiren-Amgen, Inc. | DNA sequences encoding erythropoietin |
| US4704355A (en) | 1985-03-27 | 1987-11-03 | New Horizons Diagnostics Corporation | Assay utilizing ATP encapsulated within liposome particles |
| US4798824A (en) | 1985-10-03 | 1989-01-17 | Wisconsin Alumni Research Foundation | Perfusate for the preservation of organs |
| US4835260A (en) | 1987-03-20 | 1989-05-30 | Genetics Institute, Inc. | Erythropoietin composition |
| JPH029900A (ja) * | 1988-04-12 | 1990-01-12 | Kirin Amgen Inc | 修飾エリスロポエチン |
| US5308617A (en) * | 1988-08-10 | 1994-05-03 | Halzyme Ltd. | Protein heparin conjugates |
| FR2646438B1 (fr) | 1989-03-20 | 2007-11-02 | Pasteur Institut | Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration |
| DE3923963A1 (de) | 1989-07-20 | 1991-01-31 | Behringwerke Ag | Muteine des menschlichen erythropoetins, ihre herstellung und ihre verwendung |
| CA2025907A1 (en) | 1989-09-21 | 1991-03-22 | Franklin D. Collins | Method of transporting compositions across the blood brain barrier |
| AU646822B2 (en) * | 1989-10-13 | 1994-03-10 | Kirin-Amgen Inc. | Erythropoietin isoforms |
| US5856298A (en) | 1989-10-13 | 1999-01-05 | Amgen Inc. | Erythropoietin isoforms |
| ES2127458T3 (es) | 1989-11-06 | 1999-04-16 | Cell Genesys Inc | Produccion de proteinas utilizando recombinacion homologa. |
| JP3156236B2 (ja) * | 1991-09-30 | 2001-04-16 | 雪印乳業株式会社 | 記憶障害改善治療剤 |
| NZ245015A (en) | 1991-11-05 | 1995-12-21 | Transkaryotic Therapies Inc | Delivery of human growth hormone through the administration of transfected cell lines encoding human growth hormone, which are physically protected from host immune response; the transfected cells and their production |
| US5625035A (en) * | 1992-06-05 | 1997-04-29 | The Regents, University Of California | Erythropoietin binding protein from mammalian serum |
| US6153407A (en) * | 1992-07-28 | 2000-11-28 | Beth Israel Deaconess Medical Center | Erythropoietin DNA having modified 5' and 3' sequences and its use to prepare EPO therapeutics |
| WO1994026087A2 (en) | 1993-05-14 | 1994-11-24 | Connor Kim C O | Recombinant protein production and insect cell culture and process |
| ZA946122B (en) | 1993-08-17 | 1995-03-20 | Amgen Inc | Erythropoietin analogs |
| US5830851A (en) | 1993-11-19 | 1998-11-03 | Affymax Technologies N.V. | Methods of administering peptides that bind to the erythropoietin receptor |
| US5773569A (en) | 1993-11-19 | 1998-06-30 | Affymax Technologies N.V. | Compounds and peptides that bind to the erythropoietin receptor |
| US5767078A (en) | 1995-06-07 | 1998-06-16 | Johnson; Dana L. | Agonist peptide dimers |
| US6472204B1 (en) | 1995-11-13 | 2002-10-29 | Kiyozo Asada | Methods for retroviral mediated gene transfer employing molecules, or mixtures thereof, containing retroviral binding domains and target cell binding domains |
| US5856292A (en) | 1996-04-08 | 1999-01-05 | Colgate Palmolive Company | Light duty liquid cleaning compositions |
| US5835382A (en) | 1996-04-26 | 1998-11-10 | The Scripps Research Institute | Small molecule mimetics of erythropoietin |
| WO1998018926A1 (en) | 1996-10-25 | 1998-05-07 | G.D. Searle & Co. | Circularly permuted erythropoietin receptor agonists |
| WO2000042175A1 (en) * | 1999-01-14 | 2000-07-20 | Bolder Biotechnology Inc. | Methods for making proteins containing free cysteine residues |
| DE19857609A1 (de) * | 1998-12-14 | 2000-06-15 | Hannelore Ehrenreich | Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen |
| AU784550B2 (en) * | 1999-04-13 | 2006-05-04 | Kenneth S. Warren Institute, Inc., The | Modulation of excitable tissue function by peripherally administered erythropoietin |
| PA8536201A1 (es) * | 2000-12-29 | 2002-08-29 | Kenneth S Warren Inst Inc | Protección y mejoramiento de células, tejidos y órganos que responden a la eritropoyetina |
| KR20130099071A (ko) | 2010-08-25 | 2013-09-05 | 액세스 비지니스 그룹 인터내셔날 엘엘씨 | 무선 전원 공급 시스템 및 다층 심 조립체 |
| KR101290029B1 (ko) | 2011-01-20 | 2013-07-30 | 에스티팜 주식회사 | 시타글립틴의 중간체 제조방법 |
-
2001
- 2001-12-27 PA PA20018536201A patent/PA8536201A1/es unknown
- 2001-12-28 MX MXPA03005893A patent/MXPA03005893A/es active IP Right Grant
- 2001-12-28 CN CNA018229492A patent/CN1505638A/zh active Pending
- 2001-12-28 EA EA200300738A patent/EA007967B1/ru not_active IP Right Cessation
- 2001-12-28 RS YU53103A patent/RS52276B/sr unknown
- 2001-12-28 KR KR1020087010285A patent/KR20080041755A/ko not_active Application Discontinuation
- 2001-12-28 CZ CZ20032059A patent/CZ20032059A3/cs unknown
- 2001-12-28 PE PE2011000084A patent/PE20110236A1/es not_active Application Discontinuation
- 2001-12-28 BR BR0116587-9A patent/BR0116587A/pt not_active Application Discontinuation
- 2001-12-28 EP EP10012572A patent/EP2281828A3/en not_active Withdrawn
- 2001-12-28 CN CN2011102274750A patent/CN102319421A/zh active Pending
- 2001-12-28 KR KR1020037008843A patent/KR100880201B1/ko not_active IP Right Cessation
- 2001-12-28 CA CA002432853A patent/CA2432853A1/en not_active Abandoned
- 2001-12-28 PL PL01365876A patent/PL365876A1/xx not_active Application Discontinuation
- 2001-12-28 JP JP2002555103A patent/JP2005502584A/ja active Pending
- 2001-12-28 AU AU2002239665A patent/AU2002239665B2/en not_active Ceased
- 2001-12-28 EE EEP200300267A patent/EE200300267A/xx unknown
- 2001-12-28 EP EP01987457.7A patent/EP1406922B1/en not_active Expired - Lifetime
- 2001-12-28 WO PCT/US2001/049479 patent/WO2002053580A2/en active Application Filing
- 2001-12-28 NZ NZ526722A patent/NZ526722A/en not_active IP Right Cessation
- 2001-12-28 KR KR1020097013419A patent/KR100985615B1/ko active IP Right Grant
- 2001-12-28 HU HU0302549A patent/HUP0302549A3/hu not_active Application Discontinuation
- 2001-12-28 DO DO2001P000321A patent/DOP2001000321A/es unknown
- 2001-12-28 UA UA2003077040A patent/UA91321C2/uk unknown
- 2001-12-28 ES ES01987457.7T patent/ES2564552T3/es not_active Expired - Lifetime
- 2001-12-28 NZ NZ551445A patent/NZ551445A/en unknown
- 2001-12-28 PE PE2001001314A patent/PE20020744A1/es not_active Application Discontinuation
- 2001-12-28 IL IL15639901A patent/IL156399A0/xx active IP Right Grant
- 2001-12-28 SK SK957-2003A patent/SK9572003A3/sk unknown
- 2001-12-31 UY UY27111A patent/UY27111A1/es unknown
-
2002
- 2002-01-02 AR ARP020100003A patent/AR035412A1/es unknown
- 2002-01-03 SV SV2002000814A patent/SV2003000814A/es not_active Application Discontinuation
-
2003
- 2003-06-11 ZA ZA2003/04551A patent/ZA200304551B/en unknown
- 2003-06-11 IL IL156399A patent/IL156399A/en not_active IP Right Cessation
- 2003-06-13 IS IS6843A patent/IS6843A/is unknown
- 2003-06-24 NO NO20032912A patent/NO332038B1/no not_active IP Right Cessation
- 2003-06-24 HR HR20030515A patent/HRP20030515A2/hr not_active Application Discontinuation
- 2003-07-25 BG BG108030A patent/BG108030A/bg unknown
-
2009
- 2009-09-10 JP JP2009209009A patent/JP2010031017A/ja active Pending
-
2010
- 2010-06-09 CL CL2010000606A patent/CL2010000606A1/es unknown
-
2013
- 2013-04-25 JP JP2013092598A patent/JP6114099B2/ja not_active Expired - Fee Related
-
2015
- 2015-07-15 JP JP2015141106A patent/JP2015221816A/ja active Pending
-
2016
- 2016-05-20 PH PH12016500941A patent/PH12016500941A1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20020744A1 (es) | Proteccion y mejoramiento de celulas, tejidos y organos que responden a la eritropoyetina | |
| DK1766003T3 (da) | Thrombinpræparater | |
| PE20000272A1 (es) | Formulaciones farmaceuticas de epotilonas | |
| CY1112527T1 (el) | Συνθεσεις που περιεχουν αμιοdαrονε και sulfoalkyl ether cyclodextrin | |
| DE3868438D1 (de) | Cyclosporin enthaltende pharmazeutische zubereitung. | |
| ME00408B (me) | Preparati insulina koji ne sadrže cink ili sadrže male količine cinka koji imaju poboljšanu stabilnost | |
| ES2144293T3 (es) | Preparacion estable del factor viii recombinante sin albumina que tiene un bajo contenido de azucar. | |
| BR0211071A (pt) | Conjugado polipeptìdico apresentando atividade de g-csf, método para preparar um conjugado de g-csf, composição, método para tratar um mamìfero sofrendo de um nìvel neutrofìlico insuficiente, e, uso do conjugado polipeptìdico | |
| EA200702593A1 (ru) | Высококонцентрированные композиции, применимые для борьбы с экто- и эндопаразитами | |
| AR059113A1 (es) | Composicion para administracion topica | |
| PL359624A1 (en) | Clear aqueous anaesthetic composition | |
| CN105530950A (zh) | 包含Gc-巨噬细胞活化因子的组合物及其用途 | |
| MX9401211A (es) | Composicion y procedimiento para combatir la aglomeracion de abonos. | |
| DK1171124T4 (da) | Anthelmintpræparater | |
| MX9307433A (es) | Composicion de superoxido-dismutasa estabilizada, procedimiento para su preparacion y composicion farmaceutica que la contiene. | |
| TR199902865T2 (xx) | Fizyolojiksel ortamda d���k ��z�n�rl��e sahip peptidlerin farmakolojik kompozisyonlar�. | |
| ES2292103T3 (es) | Formulacion liquida de eritropoyetina. | |
| BR0012735A (pt) | Preparação solida, e, processo para produzir preparações | |
| WO2002098465B1 (en) | Cell penetrating therapeutic agents | |
| CO5050337A1 (es) | Composiciones farmaceuticas que incluyen polipeptidos il-18 y preparacion de la misma | |
| Marquart | So-called annular gap junctions in bone cells of normal mice | |
| KR20100045503A (ko) | 피레녹신 함유 2 액성 점안제 | |
| BG106368A (en) | Pharmaceutical composition and its preparation | |
| BR9705242A (pt) | Composição parasitária injetável de longa ação e processo para preparar a mesma | |
| Shu et al. | Effects of low and high shear stress on tight junctions of endothelial cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |